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Abstract: Currently the 25-hydroxy vitamin D (25(OH)D) concentration is thought to be the best
estimate of the vitamin D status of an individual. Unfortunately, its measurement remains complex,
despite recent technological advances. We evaluated the biological variation (BV) of 25(OH)D in
order to set analytical performance specifications (APS) for measurement uncertainty (MU). Six
European laboratories recruited 91 healthy participants. The 25(OH)D concentrations in K3-EDTA
plasma were examined weekly for up to 10 weeks in duplicate on a Lumipulse G1200 (Fujirebio,
Tokyo, Japan). The linear regression of the mean 25(OH)D concentrations at each blood collection
showed that participants were not in a steady state. The dissection of the 10-sample collection into
two subsets, namely collections 1–5 and 6–10, did not allow for correction of the lack of homogeneity:
estimates of the within-subject BV ranged from 5.8% to 7.1% and the between-subject BV ranged from
25.0% to 39.2%. Methods that would differentiate a difference induced by 25(OH)D supplementation
at p < 0.05 should have MU < 13.6%, while at p < 0.01, the MU should be <9.6%. The development of
APS using BV assumes a steady state of patients. The findings in this study suggest that patients are
not in steady state. Therefore, APS that are based on MU appear to be more appropriate.
Keywords: analytical performance specifications biological variation; measurement uncertainty;
vitamin D; 25(OH)-vitamin D
1. Introduction
Twenty-five-hydroxy vitamin D (25(OH)D) measurement remains complicated de-
spite recent technological advances [1]. Indeed, 25(OH)D assays must recognize both
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25(OH)D2 and 25(OH)D3 equivalently; 25(OH)D is very lipophilic and needs to be re-
moved from its major carrier form, vitamin D binding protein (DBP), and physiological
or pathological conditions such as pregnancy, estrogen therapy, or renal failure often lead
automated immunoassays to fail in correctly quantitating 25(OH)D [2]. On the other
hand, the standardization of 25(OH)D measurements is an ongoing process led by the
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), the Vi-
tamin D Standardization Program (VDSP), and the Centers for Disease Control (CDC)
Vitamin D Standardization Certification Program (VDSCP) [3]. This process is a prerequi-
site for the achievement of comparable results across different measurement methods and
across manufacturers.
The aim of these standardization programs is that 25(OH)D measurements are accu-
rate, as well as comparable over time, location, and laboratory procedure, to the concen-
trations obtained using Joint Committee for Traceability in Laboratory Medicine (JCTLM)
recognized reference measurement procedures (RMPs), such as those operated at the
National Institute of Standards and Technology (NIST) [4], Ghent University [5], or the
CDC [6]. By linking the measurements performed in patient care to these RMPs, metro-
logical traceability as outlined in the International Organization for Standardization (ISO)
document 17511 can be achieved. ISO 17511 does not provide analytical performance
specifications. These have been proposed by the clinical laboratory community and have
been adopted in these standardization programs. Assays are considered traceable to In-
ternational System (SI) units when they are calibrated to a JCTLM—recognized RMP, and
they are considered standardized when their calibration bias, expressed as mean bias, is
<5% to the RMP and the assay imprecision, expressed as mean coefficient of variation, is
<10% [7]. The CDC Vitamin D Standardization-Certification Program (VDSCP) determines
the calibration bias and imprecision by evaluating the data obtained from 40 blinded single-
unit, fresh-frozen serum samples measured in batches of 10 samples over four consecutive
quarters. With improvements in calibration bias among assays, the measurement bias
observed in individual samples became more apparent. To assist assay manufacturers and
users of assays, the CDC VDSCP started to provide information on individual sample pass
rates, which represents the proportion of the 40 samples that met the bias criterion (<5%).
In June 2020, 34 methods, from either in-vitro diagnostics (IVD) manufacturers or in-house
methods developed in medical laboratories, were considered certified by CDC VDSCP and
standardized against the RMP for the year 2019. However, the “individual sample pass
rate” in 2019 was quite different from one method to the other and ranged from 45% to 88%
with liquid chromatography tandem mass spectrometry (LC-MS/MS) methods (mean pass
rate of 63%) and from 8% to 68% for immunoassays (mean pass rate of 30%). The list of
these standardized participants and their respective methods can be found on the VDSCP
portion of the CDC’s external website [8].
The criteria for an acceptable method of CV < 10% and a mean bias < 5% were taken
from Stöckl et al. [7], who used data from multiple studies and diverse study popula-
tions. With the aim of defining analytical performance specifications (APS) for a reference
measurement system for 25(OH)D, four of the five models in the hierarchy set at the
1999 Stockholm Consensus Conference on Setting Global Analytical Goals in Laboratory
Medicine [9] were reviewed. The models were as follows: (1)—misclassifications in di-
agnosis; (2)—biological variation (BV) data mainly derived from the reference interval
(RI) but also from an evaluation of 25(OH)D monitoring: (3)—expert recommendations;
and (4)—APS set by (a) regulatory bodies, (b) organizers of External Quality Assessment
Schemes (EQAS), and (c) the state-of-the-art performance. The APS used in the VDSP and
VDSCP are based on Model 2.
However, as the recommendations of Stöckl et al. were published in 2009 [7], there
have been many developments that impinge on their conclusions. Firstly, there is a
new simpler approach advocated by the European Federation of Clinical Chemistry and
Laboratory Medicine (EFLM) to set APS using three models, namely: (1)—clinical outcomes,
(2)—BV, and (3)—state-of-the-art performance [10]. Secondly, as shown in the EFLM BV
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database [11], there have been additional publications on the BV of 25(OH)D, but the results
for the within-subject BV (CVI) range from 6.9% [12] to 21.2% [13], with the between-subject
BV (CVG) being greater than 40% [14]. Thirdly, there has been significant improvement
in the “state-of-the-art” performance over the last decade, mainly because of the various
standardization activities. As a result, the application of Model 2, where the APS is based on
BV, is favored [15]. This is also the case for the generation of APS for standard measurement
uncertainty (MU) [16]. MU is a non-negative parameter characterizing the dispersion of
the quantity values being attributed to a measurand, based on the information used.
The measurement uncertainty typically accounts for the combined effect of random (i.e.,
imprecision) effects and remaining systematic (i.e., bias) uncertainty following imperfect
correction. The aim of this study was to evaluate the BV of 25(OH)D in samples obtained
in the large European Biological Variation (EuBIVAS) study [17], which recently adopted
a recommendation for the generation of BV components [18], and to see if we could
significantly update the model proposed by Stöckl et al. [7].
2. Materials and Methods
2.1. Biological Variation Data Derived from the EuBIVAS
The EuBIVAS has been described in detail elsewhere [17]. Briefly, six European labora-
tories located in Milan (Italy, 45.47◦ N, 9.19◦ E), Padua (Italy, 45.41◦ N, 11.87◦ E), Bergen
(Norway, 60.39◦ N, 5.33◦ E), Madrid (Spain, 40.42◦ N, 3.70◦ W), Assen (The Netherlands,
52.99◦ N, 6.6◦ E), and Istanbul (Turkey, 41.01◦ N, 28.97◦ E) were involved. At the beginning
of the study, 105 subjects were recruited. Three subjects were not included in the final
cohort after the application of the inclusion/exclusion criteria during the first collection,
and five people withdrew during the study for personal reasons.
The final study population for sample collection consisted of 97 presumed healthy
volunteers. Further exclusions from the final cohort were based on the laboratory mea-
surements made at each visit. In particular, two males were excluded for suspicions of
subclinical viral infection as a result of a significant negative trend in γ-glutamyl transferase
(GGT) and alanine aminotransferase (ALT) activities; two further males were excluded
because of raised creatine kinase (CK) and raised ALT on a number of occasions; another
male for an unknown liver problem with elevated ALT during several collections; and a
further male with elevated ALT (three collections), CK (one unusual value), and C-reactive
protein (CRP) (three unusual concentrations) [17]. This led to further exclusion of six
subjects, resulting in the recruitment of 91 presumed healthy participants (38 males and
53 females; age range of 21–69 years;
The participants completed an enrollment questionnaire to provide information on
their lifestyle and presumed health status, which was further verified by a set of routine
laboratory tests performed during each collection. One potential participant was taking
vitamin D supplementation and was thus excluded. All laboratories followed the same
protocol for the pre-examination phase. Fasting blood samples were drawn by venipunc-
ture weekly for 10 consecutive weeks (April–June 2015) on a set day (Tuesday to Friday),
and at the same time (e.g., between 08:00 a.m. and 10:00 p.m. at each weekly visit) by
the same phlebotomist at most visits, further minimizing variation. The number of col-
lections per subject means that the resultant data will be from studies of a high statistical
power, delivering high quality estimates of the components of examination and biological
variation with tight confidence intervals [19]. In total, 77 participants completed all 10 col-
lections, 10 participants completed 9 collections, 2 participants completed 8 collections,
and 2 participants completed 7 collections. The K3-EDTA plasma samples collected by
each laboratory were sent frozen on dry ice to San Raffaele Hospital, Milan, Italy. The
samples were stored in a −80 ◦C freezer until they were shipped on dry ice to the Centre
Hospitalier Universitaire (CHU) de Liège, Belgium, where the 25(OH)D concentrations
were determined in May 2020. Although we have no data on the five—year stability of
25(OH)D at −80 ◦C under our conditions, different pre-examination studies have shown
that this measurand is remarkably stable, even under extreme conditions [20,21].
Nutrients 2021, 13, 431 4 of 13
The study was approved by the Institutional Ethical Review board of San Raffaele
Hospital (Milan, Italy; protocol number: WG-BV project #001, 50/INT 2014) in agreement
with the World Medical Association Declaration of Helsinki (as revised in 2013) and by
the Ethical board/ regional Ethics Committee for each involved center (protocol number:
WG-BV project #001, PI-1993. April 2015 for Spain; WG-BV project #001, 2014-26 for
The Netherlands; WG-BV project #001, 3452/AO/15 for PD Italy; 2015-3/17 for Turkey;
2014/1988 for Norway). Figure 1).
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Figure 1. Selection of the participants for the European Federation of Clinical Chemistry and
Laboratory Medicine European Biological Variation Study (EuBIVAS) study. ALAT: alanine amino-
transferase; CK: creatinine kinase; CRP: C-reactive protein.
2.2. Data Analysis
The data analysis was performed as previously described [22,23]. Briefly, CVI was
estimated using one way analysis of variance (CV-ANOVA) for all participants, as well as
for males and females separately. Outlier identification and removal were performed for
replicates and samples on the CV-transformed data, by assessing homogeneity of the mea-
surement CV (CVA; between-replicates) using the Bartlett test, and the homogeneity of CVI
using the Cochran test, as recommended and applied in the European Federation of Clini-
cal Chemistry and Laboratory Medicine European Biological Variation Study (EuBIVAS)
strategies [17]. The CVG estimates were estimated on natural log-transformed data.
To examine if there was a general trend in the overall concentration over the study
period, and if individual participants were in steady state, we calculated the regression of
the mean of the 180 duplicate measurements from every blood draw (1, 2 . . . . 10) (pooled
mean group sample concentrations) versus the blood draw number (1–10). Subjects were
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considered in steady state if the 95% confidence intervals (CI) of the slope of the regression
line included zero.
BV data estimation after outlier exclusion and trend analysis were both performed for
the whole data set derived from 10 blood collections, as well as for the data derived from
the first five collections (April–May) and the data from the last five collections (May–June).
The results for the 25(OH)D mean values, CVI and CVG, and the estimates between
the male and female subgroups were considered significantly different if the associated 95%
CI did not overlap. Data analyses were performed using Microsoft Excel 2010 (Microsoft,
Redmond, WA, USA) and IBM SPSS (Chicago, IL, USA) v23.
2.3. Analytical Methods
We measured the 25(OH)D concentrations with the Fujirebio assay on a Lumipulse
G1200 instrument (Fujirebio, Tokyo, Japan). This method is the only non-competitive
immunoassay (sandwich) method for 25(OH)D measurement [24], the performance char-
acteristics of which surpass the VDSP criteria for acceptability [7] and had an individual
sample pass rate of 68% in 2019, according to the CDC VDSCP certification report [8].
All of the measurements were performed according to the manufacturer’s instructions in
the clinical chemistry laboratory of CHU de Liège. The manufacturer’s internal quality
control materials (two concentrations) were measured at the beginning and end of each
run, following the validation of the calibration curves by the instrument. Samples donated
from each participant were measured in duplicate within the same run on a single day.
3. Results
3.1. APS for 25(OH)D Based upon Biological Variation Derived from the EuBIVAS, EFLM Model 2
The median number of participants per center was 15 (range: 12–19). The participants
were generally physically active and approximately 3% were regular smokers (the detailed
demographic characteristics are documented in previous publications) [17,25]. Their
median body mass index (BMI) was 22.5 kg/m2 (range of 17.6–32.5 kg/m2) and none
of the participants suffered from renal impairment.
The overall mean 25(OH)D concentration was 19.0 (95% confidence interval (CI):
18.6–19.4%) ng/mL and the mean CVA, determined from the duplicate examinations,
was 1.7% (95% CI: 1.6–1.8%). The differences in concentrations between males, with
lower concentrations, and females were identified by the lack of overlap of 95% CIs, so
that different CVG were estimated for males and females, respectively. No significant
differences between CVI estimates between males and females were observed (Table 1).
A linear regression of the mean of all of the concentrations from each blood drawing
against the blood drawing number was performed. This regression showed that the
participants were not in a steady state with regard to 25(OH)D concentrations, as the 95%
CI of the slope did not include zero. Figure 2 shows that, irrespective of the geographical
location of the participants, 25(OH)D concentrations tended to linearly increase according
to the time of sampling during this European Spring in 2015. Hence, this set of data could
not be considered homogenous according to the Cochran test [26], a prerequisite for the
estimation of CVI and CVG. The homogeneity of the data was achieved only by eliminating
more than 50% of the data, thus reducing the CVI from 17.8% (whole population, original
data) to 6.3% (95% CI: 5.9–6.8%; 41 subjects; Table 1). The dissection of the entire 10 sample
collections into two subsets, i.e., the first set being collections 1 to 5, and the second set
being collections 6 to 10, did not correct the lack of homogeneity issue, resulting in the
detection of outliers in about 13% of the data. The CVI ranged from 5.8% to 7.1% according
to the sex and subset of the collection (Table 1). The CVG ranged from 25.0% to 39.2%.
These results clearly showed that the traditional BV concept, in which a measurand varied
around a homeostatic setting point (CVI) with differences among homeostatic setting points
(CVG), was quite inappropriate for 25(OH)D.
Nutrients 2021, 13, 431 6 of 13
Table 1. Examination coefficient of variation (CVA), within-subject (CVI), and between-subject (CVG) biological variation estimates with 95% confidence intervals (CI) of twenty-five-
hydroxy vitamin D (25(OH)D).






CVA (%) CVI (%) CVG (%) n Results Eliminated %
Original data 90 1696 9.52 1.96 19.0(18.6–19.4)
1.7
(1.6–1.8) 17.8 1 subject for Vitamin D consumption from Padua, Italy
All results from
10 collections
















































* Corresponds to the number of replicates: If we have 10 samples for a subject, with 2 replicates, this means we have 20 numbers. If we have 19 numbers, it means one replicate is not included and the mean
number of replicates in this case is 19/10 = 1.9.
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. . for ( ) ase o t e ffect of o a e i erial es lts, o el
i r t at, although the mean 25(OH)D concentration for the group var-
ied from geographical location t location (i.e., the intercepts di fered), l t
li i f r t (i. ., t e
slopes differed), the data represent the “physiological” variation in these European partici-
pants during Spring 2015. Hence, the entire data set might be used for further assessment
using a strategy that could be judged as an approach to EFLM Model 1 for the derivation
of APS, a strategy based on the assessment of the effect of the examination performance
on clinical outcomes. Figure 3 shows the regression of the mean of the 180 values of
sample collection versus the study week. The mean difference in concentration between
consecutive samples was 2.8%. An examination method that would be able to significantly
differentiate a physiological weekly variation of 25(OH)D concentration should possess
performance characteristics, i.e., measurement uncertainty (MU), that can be calculated
as follows:
Change (%) = 21/2 × MU (%) × Z
where Z is the Z-score, i.e., the number of standard deviations (SD) appropriate to the
probability. In this case, the variation is an increase, so the statistical approach must be
one-sided and for a 95% probability, Z is 1.645. So, 2.8 = 21/2 × MU (%) × 1.645, and the
Nutrients 2021, 13, 431 8 of 13
APS of a method used to detect a significant physiological change, p < 0.05, should have a
MU < 1.2%.
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measuring/monitoring the 25(OH)D concentration should at least be three months [27].
The regression shows that the physiological variation of the 25(OH)D concentration in
participants over a 10-week period was 31.6%. According to the equations provided above,
that is, 31.6% = 21/2 × MU (%) × 1.645, a method that would differentiate a physiological
change from a change induced by vitamin D supplementation at p < 0.05, should have a
MU < 13.6%. If it was deemed clinically necessary to be more certain that an increase had
occurred, for example, at p < 0.01, the appropriate Z-score should be 2.326 so that the APS
for the MU would be 9.6%, as the formula would become 31.6% = 21/2 × MU (%) × 2.326.
4. Discussion
Vitamin D deficiency has become a worldwide problem [28]. The accurate determi-
nation of 25(OH)D to assess deficiency and its medication is thus mandatory, and VDSP
and CDC VDSCP have been efficiently working over recent years to promote the standard-
ization of the examination methods. It should be realized that all of these standardization
efforts applied the APS developed by Stöckl et al. [7] and recommended by the clinical
laboratory community. The strategies that were used to derive APS for RMP and for clinical
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diagnosis and monitoring were based on the internationally well-accepted hierarchy of
approaches, which were agreed upon at the 1999 Stockholm Consensus Conference on
Setting Global Analytical Goals in Laboratory Medicine [9]. However, since then, a new
simpler approach from the EFLM advocates setting APS using the following three models:
(1)—clinical outcomes, (2)—BV, and (3)—state-of-the-art performance [9]. We examined
both Model 2, as it is widely considered the best general approach [15], and Model 1, in
order to assess the APS required to detect a significant or highly significant change in
25(OH)D concentration over one week and three months.
Herein we showed, for the first time, two very important points. The first is that the
traditional approach to the generation and application of data on BV is not applicable to
25(OH)D. Indeed, the results of our study show that there is no steady state in 25(OH)D
concentrations over time, and that the application of any model based on random variation
around homeostatic setting points is inappropriate. This finding may seem obvious, as it
has been known for decades that 25(OH)D concentrations observed in summer are higher
than those observed in winter [29], but we have demonstrated this for the first time for a
cohort of presumably healthy individuals. The immediate application of this finding is that
any APS for 25(OH)D based on BV estimates are simply inappropriate.
As a consequence, another approach to determine APS for 25(OH)D examinations
is required. The approach that we propose in this paper is to use MU. However, section
5.5.1.4 of ISO 15189 requires that laboratories must determine the standard MU for each
measurement procedure in the examination phase used to report the measured quantity
values on patients’ samples and then apply a coverage factor to use in routine practice [30].
MU includes components arising from systematic effects. Sometimes estimated systematic
effects are not corrected for the method as they should be following metrological principles,
but, instead, associated MU components are incorporated [31]. In patient care settings,
patient data are typically based on single measurements, and every individual component
contributing to the MU of the measurement cannot be corrected for, but generally applicable
estimates obtained correctly are valuable in aiding the interpretation of all results. To date,
APS for MU have never been published for 25(OH)D. Hence, the second important point
of this current work is that we propose APS for MU based on the physiological variation
of 25(OH)D concentrations over time. Our results show that, in a European population,
25(OH)D concentrations increased by 2.8% weekly over Spring, and that after 10 weeks, the
mean increase was 31.6%. Interestingly, the concentrations observed in the placebo group
(n = 48) in a randomized controlled trial set in Liège (50.57◦ N, 5.57◦ E) during Autumn
decreased by a mean of 39.6%, which is approximately the same order of magnitude as the
increase observed during Spring in this study [32]. Thus, we believe that the probability
of detection of 25(OH)D variation over a certain period of time could become the new
paradigm to evaluate 25(OH)D examination methods. Accordingly, we propose that higher
order reference methods should present a MU < 1.2%, —and “routine” assays should
present a MU < 13.6% to detect a difference (increase) at p < 0.05 and 9.6% to detect a
difference at p < 0.01, this latter APS is, interestingly, almost the same as the current APS
for the CVA in the VDSP of 10%. Using a similar strategy, MU targets for higher—order
non-reference methods could be based on the probability of detecting a significant change
over a five-week period, which, according to the equations and data above, would be
a MU < 6.2% at p < 0.05. This is totally compatible with the proposal of Stepman and
Thienpont [33] in a letter on the first paper published on the MU of 25(OH)D [34].
EQAS are insufficient to assess the entire MU [35,36]. Accuracy-based EQAS does
provide higher-order (reference) target concentrations for its materials, which can be used
to assess bias/systematic error. This remains an indication, at best, of the true bias of
the method being evaluated [35]. From a very practical point of view, the MU could be
provided by EQAS providers and by the CDC VDSCP in the certification of the methods.
The MU of the VDSCP certified LCMS/MS of CHU de Liège calculated on the 25(OH)D
concentrations of the 40 samples received was found to be 5.9%, which is very close to the
APS of <6.2% described above. On the other hand, ProBioQual (Lyon, France), a French
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EQAS provider, proposes the calculation of a MU based on the target value of the peer
group, as well as targets based on BV (when available). In 2019, the MU of our routine
method (DiaSorin Liaison, Saluggia, Italy) was 16.3%, a little lower than the median of
DiaSorin users, but higher than the APS we proposed for a routine method (MU < 13.6%).
Finally, the Advisory Panel of the Vitamin D External Quality Assessment Scheme (DEQAS,
London, UK) recently proposed providing an MU on the target values assigned by the
RMP method on each sample sent to participating laboratories [37]. The combined mean
uncertainty of the last distribution in April 2020 (samples 571–575) was 1.3%, which is
totally compatible with the MU APS set for the RMP that we proposed.
Standardization programs typically start with an assessment of the examination
performance using specimens obtained from the general population, and then include
specimens from special subpopulations as recommended by professional organizations.
For 25(OH)D, different studies have shown 25(OH)D to behave differently according to the
health status of the patient [24,38–40]. In situations that do not allow for the assessment
of systematic and random effects of health status on examination performance, the use of
MU could allow for estimating the importance of those variations according to the APS for
MU based on the physiological variation of 25(OH)D. Further studies are needed to assess
whether MU will help to better identify and improve the sample-specific bias currently
observed with vitamin D assays.
5. Limitations
It needs to be noted that the APS suggested here are derived from a European popula-
tion, and further studies are needed to assess whether these findings can be generalized
to populations that are highly diverse with regards to race/ethnicity. We also chose to
run an immuno-assay and not our VDSCP certified Liquid Chromatography coupled to
tandem Mass Spectrometry method (LCMS-MS) to examine the samples based on several
cogent reasons, including the sample volume availability, ability to do long runs, and low
imprecision. However, we also examined many of the samples using the LCMS-MS method
and the excellent correlation is shown in Supplementary Figure S1. These demonstrate that
the impact of the method used to generate the data herein is likely negligible.
6. Conclusions
In conclusion, this unique study, which has resulted in a position statement from the
IFCC Committee on Bone Metabolism (C-BM), provides evidence that the APS recom-
mended by the clinical laboratory communities and developed by Stöckl et al. more than a
decade ago [7] could evolve to include MU. Further studies are needed to assess whether
such changes will help to improve the measurement accuracy and reliability of vitamin
D assays.
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